MedTrace Logo

Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression

NCT01681446 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 296

Last updated 2018-06-01

No results posted yet for this study

Summary

The purpose of the study is to determine whether interferon-alpha is effective in prevention of tumor recurrence for the patients with a low miR-26 expression in tumor after curative resection of hepatocellular carcinoma.

Conditions

Interventions

DRUG

interferon-alpha (IFN-alpha)

interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Jia Fan, MD, PHD · Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China

  • Xin Wei Wang, PhD · National Cancer Institute, NIH, US

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01681446 on ClinicalTrials.gov